Immutep is participating in the upcoming Jefferies Global Healthcare Conference in NYC. CEO Marc Voigt will present a company overview on Thurs, June 5th at 11:40am ET (US). A live webcast and replay of the presentation will be available here: wsw.com/webcast/jeff31…

Immutep announces positive initial efficacy data & continued favourable safety from first-in-human Phase I evaluating IMP761, a first-in-class #LAG3 agonist antibody. The substantial reduction in T cell activity at 0.9mg/kg dosing level highlights the potential efficacy of

Immutep’s CEO Marc Voigt appeared on @ShareCafe’s latest episode of Table for Two, where he shared clinical trial updates across Immutep’s oncology and autoimmune programs. Marc discusses the results from the TACTI-003 and INSIGHT-003 trials in head & neck cancer and in

Immutep is pleased to share that three abstracts for clinical trials evaluating its first-in-class MHC Class II agonist, efti, have been accepted for presentation at the ESMO - Eur. Oncology Congress 2025 taking place from the 17th - 21st of October in Berlin, Germany. Details of the

Immutep today announces an upcoming poster presentation for the pivotal TACTI-004 (KEYNOTE-F91) Phase III trial at the IASLC 2025 World Conference on Lung Cancer (WCLC), taking place in Barcelona, Spain, from the 6th - 9th of September 2025. The poster presentation will

Immutep is pleased to provide an update on its activities for the quarter ended 30 June 2025 (Q4 FY25). Highlights include: - TACTI-004 Phase III trial in first-line non-small cell lung cancer (1L NSCLC) continues to build momentum and is recruiting patients at multiple sites

Immutep has received positive and constructive feedback from the US FDA regarding potential late stage clinical development of eftilagimod alfa for first line treatment of head and neck squamous cell carcinoma patients with PD-L1 expression below 1 (CPS <1).  Read more here:

We’re pleased to announce Immutep CEO Marc Voigt will join the Ausbiz Investor Connect session on 19 Aug at 1pm AEST.  Join us for an insightful conversation and opportunity to learn more about Immutep’s progress & strategy. Register here: info.ausbiz.com.au/ausbiz-capital… #Immutep

Immutep's CEO Marc Voigt recently joined the ausbiz Investor Connect session where he provided an update on the company’s pivotal TACTI-004 Phase 3 trial in first line #NSCLC, its clinical-stage IMP761 immunotherapy for autoimmune diseases, upcoming milestones, and more.

Immutep's CEO, Marc Voigt spoke with 7News Boston WHDH Perth as Immutep's pivotal Tacti-004 Phase III trial opens to patients in Western Australia. Globally the Phase III trial will recruit over 750 patients across more than 150 clinical sites. This final stage of testing is focused on

Immutep's CEO Marc Voigt joined Make Accounting Great Again's Nadine Blayney for a discussion covering a variety of topics including progress on the registrational TACTI-004 Phase 3 trial in non-small cell lung cancer, recent FDA feedback on late-stage clinical development of efti in head & neck

Immutep is pleased to share its 2025 Annual Report today. Read the full report here: bit.ly/426U4em Chairman Dr Russell Howard said: "FY26 promises to be another year of meaningful progress. You can expect continued momentum for TACTI-004, updates from AIPAC-003,

Immutep is pleased to announce an abstract for the EFTISARC-NEO Phase II investigator-initiated trial has been accepted for oral presentation at the CTOS 2025 Annual Meeting taking place 12-15 November 2025, in Boca Raton, Florida. For more details see

Immutep CEO Marc Voigt will be joining the ShareCafe- Sip and Learn webinar this Thursday, 11 September at 12:30pm AEST. Marc will deliver a company presentation and take part in the Q&A session. Use this link to register if you'd like to join in! bit.ly/4nnNdFL

Immutep CEO Marc Voigt recently joined Sharecafe Lauren Hays to share an updated company presentation and discuss Immutep's latest developments. Marc spoke about: - Progress of the pivotal TACTI-004 Phase 3 trial in first-line non-small cell lung cancer, run in

We’re pleased to share that George Washington University Cancer Center, will launch an investigator-initiated Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in HR+/HER2-neg breast cancer patients. The trial is led

Immutep announces update for pivotal TACTI-004 Phase III in 1L NSCLC. Immutep has now enrolled & randomised over 170 patients, an important milestone as this is above the # required to conduct the futility analysis, which remains on track for Q1 2026. Additionally, the # of

Immutep is pleased to complete another productive meeting with the FDA regarding the eftilagimod alfa (efti) program. We welcome the positive feedback and the agreement on efti's optimal biological dose is another important building block for future potential BLA filings.

Immutep is pleased to share positive clinical data presented at the ESMO - Eur. Oncology Congress 2025. Key highlights: - EFTISARC-NEO Phase II: Met primary endpoint, with the novel combination including efti achieving 51.5% tumour hyalinization/fibrosis in soft tissue sarcoma (p < 0.001).